534 related articles for article (PubMed ID: 33255895)
1. DC-Based Vaccines for Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33255895
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009
[TBL] [Abstract][Full Text] [Related]
3. Plasmacytoid Dendritic Cells and Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Cells; 2022 Jan; 11(2):. PubMed ID: 35053338
[TBL] [Abstract][Full Text] [Related]
4. DC-Derived Exosomes for Cancer Immunotherapy.
Yao Y; Fu C; Zhou L; Mi QS; Jiang A
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359569
[TBL] [Abstract][Full Text] [Related]
5. Human CD34
van Eck van der Sluijs J; van Ens D; Brummelman J; Heister D; Sareen A; Truijen L; van Ingen Schenau DS; Heemskerk MHM; Griffioen M; Kester MGD; Schaap NPM; Jansen JH; van der Waart AB; Dolstra H; Hobo W
Cell Mol Life Sci; 2023 Sep; 80(10):298. PubMed ID: 37728691
[TBL] [Abstract][Full Text] [Related]
6. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
[TBL] [Abstract][Full Text] [Related]
7. Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.
Zhang Y; Chen G; Liu Z; Tian S; Zhang J; Carey CD; Murphy KM; Storkus WJ; Falo LD; You Z
J Immunol; 2015 Jun; 194(12):5937-47. PubMed ID: 25972487
[TBL] [Abstract][Full Text] [Related]
8. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
9. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
Nierkens S; den Brok MH; Garcia Z; Togher S; Wagenaars J; Wassink M; Boon L; Ruers TJ; Figdor CG; Schoenberger SP; Adema GJ; Janssen EM
Cancer Res; 2011 Oct; 71(20):6428-37. PubMed ID: 21788345
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.
Cooles FAH; Anderson AE; Skelton A; Pratt AG; Kurowska-Stolarska MS; McInnes I; Hilkens CMU; Isaacs JD
Front Immunol; 2018; 9():755. PubMed ID: 29867920
[TBL] [Abstract][Full Text] [Related]
12. Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
Schreibelt G; Duiveman-de Boer T; Pots JM; van Oorschot TGM; de Boer AJ; Scharenborg NM; van de Rakt MWMM; Bos K; de Goede AL; Petry K; Brüning M; Angerer C; Schöggl C; Dzionek A; de Vries IJM
Methods Cell Biol; 2024; 183():33-50. PubMed ID: 38548417
[TBL] [Abstract][Full Text] [Related]
13. Plasmacytoid Dendritic Cells as Cell-Based Therapeutics: A Novel Immunotherapy to Treat Human Immunodeficiency Virus Infection?
van der Sluis RM; Egedal JH; Jakobsen MR
Front Cell Infect Microbiol; 2020; 10():249. PubMed ID: 32528903
[TBL] [Abstract][Full Text] [Related]
14. Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities.
Fu C; Ma T; Zhou L; Mi QS; Jiang A
Immunol Invest; 2022 Nov; 51(8):2133-2158. PubMed ID: 35946383
[TBL] [Abstract][Full Text] [Related]
15. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
Huber A; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2804. PubMed ID: 30559743
[TBL] [Abstract][Full Text] [Related]
16. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
17. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells.
Koyama M; Hashimoto D; Aoyama K; Matsuoka K; Karube K; Niiro H; Harada M; Tanimoto M; Akashi K; Teshima T
Blood; 2009 Feb; 113(9):2088-95. PubMed ID: 19144988
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells.
Moffat JM; Cheong WS; Villadangos JA; Mintern JD; Netter HJ
Vaccine; 2013 Apr; 31(18):2310-6. PubMed ID: 23473776
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
20. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.
Tel J; Schreibelt G; Sittig SP; Mathan TS; Buschow SI; Cruz LJ; Lambeck AJ; Figdor CG; de Vries IJ
Blood; 2013 Jan; 121(3):459-67. PubMed ID: 23212525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
